
The study evaluated acute and chronic estimated glomerular function (eGFR) slopes in the 2 largest completed trials testing steroidal MRAs in chronic HF. The study conducted parallel post hoc eGFR slope analyses in 2 multinational, double‐blind, randomized, placebo‐controlled trials of steroidal MRAs in chronic HF with reduced ejection fraction (EMPHASIS‐HF) and preserved ejection fraction (TOPCAT Americas region). Steroidal MRAs result in acute declines in eGFR but do not modify long‐term kidney disease trajectories in chronic HF with reduced or preserved ejection fraction.
Like
Save
Share